Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)

NCT00293111 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00293111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00293111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2002
Completion date
Not reported
Enrollment
30
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma